基于转氨酶阈值的瑞德西韦停药决策:一项观察性登记研究
本研究基于美国FDA ACMT COVID-19 ToxIC药物警戒登记项目,回顾性分析18个月内116例使用瑞德西韦后转氨酶升高的COVID-19患者,描述真实实践中因转氨酶升高而提前停用瑞德西韦的阈值。结果显示37例(31.9%)因转氨酶升高提前停药,停药时ALT中位值为200 U/L,仅21.6%符合FDA停药标准、40.5%符合EMA标准,提示临床决策较说明书推荐更为保守且阈值差异大。
要点
- 真实实践中因转氨酶升高提前停用瑞德西韦的比例为31.9%(37/116)。
- 提前停药时ALT中位阈值为200 U/L(IQR 145-396),仅21.6%符合FDA标准。
- 临床停药决策较说明书推荐更为保守,且不同中心阈值差异较大。
核心结论
- 在美国真实实践中,临床医生因转氨酶升高停用瑞德西韦的决策总体较药品说明书推荐更为保守,且所用阈值差异较大。
研究设计与样本
- 基于美国FDA ACMT COVID-19 ToxIC(FACT)药物警戒登记项目的描述性研究,纳入17个参与卫生系统,回顾性识别18个月(2020年11月23日至2022年5月18日)内的病例。
- 从FACT登记处1026例中纳入116例完成转氨酶升高补充数据表的病例,纳入标准为ALT翻倍或升高≥50 U/L。
主要发现
- 116例中,47%在瑞德西韦治疗前已有ALT升高;用药期间ALT较基线升高中位92 U/L(IQR 51-164,最大8350)。
- 37例(31.9%)因转氨酶升高提前停用瑞德西韦,停药时ALT中位阈值200 U/L(IQR 145-396,范围92-5743)。
- 提前停药患者中,仅21.6%符合FDA考虑停药标准,40.5%符合既往EMA考虑停药标准。
关键数值与推荐
- FDA与EMA关于因ALT升高考虑停用瑞德西韦的阈值不同。
- 本研究中提前停药时ALT中位值为200 U/L(IQR 145-396,范围92-5743)。
- 提前停药病例中符合FDA停药标准的比例为21.6%,符合EMA标准的比例为40.5%。
临床怎么用
- 临床药师可参考本研究提示的真实世界停药阈值分布,但需注意其与说明书标准的差异。
- 应关注瑞德西韦治疗前已有ALT升高(47%)及用药期间ALT动态变化,结合官方标签阈值个体化评估停药时机。
局限性
- 本研究为描述性设计,基于登记项目的回顾性数据,停药分类依赖治疗团队的病历记录。
- 样本仅来自美国17个卫生系统,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Remdesivir is an antiviral approved by the US Food and Drug Administration (FDA) for treatment of coronavirus disease 2019 (COVID-19), and aminotransferase elevation is commonly reported. Thresholds to be considered for discontinuation due to alanine aminotransferase (ALT) elevation differ between the FDA and European Medicines Agency (EMA). The primary objective was to describe aminotransferase thresholds being used in real-world practice for discontinuation of remdesivir in patients with COVID-19, and compare them with labeled recommendations. METHODS: This study used a descriptive design based on an ongoing national registry of adverse events, the FDA ACMT COVID-19 ToxIC (FACT) pharmacovigilance project, with 17 participating health systems in the USA. Cases were identified retrospectively for an 18-month period (23 November 2020-18 May 2022). Classification of discontinuation as premature and due to aminotransferases was based on chart documentation by the treating team. RESULTS: Of 1026 cases in the FACT registry, 116 cases were included with supplemental data forms completed for aminotransferase elevation with remdesivir, defined a priori for inclusion as ALT doubling or increasing by ≥ 50 U/L. ALT was elevated prior to remdesivir in 47% and increased above baseline during dosing by a median of 92 U/L [interquartile range (IQR) 51-164, max 8350]. Remdesivir was discontinued early in 37 (31.9%) patients due to elevated aminotransferases. The ALT threshold for premature discontinuation was median 200 U/L (IQR 145-396, range 92-5743). Among patients with premature discontinuation of remdesivir for aminotransferase elevation, only 21.6% met FDA criteria to consider discontinuation, and 40.5% met prior EMA criteria to consider discontinuation. CONCLUSION: In this descriptive study of real-world practice in the USA, clinicians are overall making more conservative treatment decisions than are recommended for consideration in approved drug labeling of discontinuation, with wide variation in the aminotransferase thresholds being used.
引用
- Schimmel J, Epperson LC, Aldy K, et al. Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry. Drugs. 2024. PMID: 38198063. doi:10.1007/s40265-023-01981-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。